Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
Henrike ArfstenGeorg GoliaschPhilipp E BartkoPhilipp E BartkoGeorg SpinkaAnna ChoJohannes NovakHelmuth HaslacherGuido StrunkJoachim StruckMartin HülsmannNoemi PavoPublished in: British journal of clinical pharmacology (2020)
The significant increase of MR-proADM and bio-ADM together with an elevated bioADM/MR-proADM ratio suggest both enhanced formation and reduced breakdown of bioactive ADM following the initiation of ARNi. Activation of the ADM-axis represents a so far unrecognized effect of ARNi.